Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ...

View original at finance.yahoo.com
Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ... This article first appeared on GuruFocus. Net Sales: $25.4 billion, a 6.7% increase from last year…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Operating margin rate of 4.5% was 80 basis points higher than last year's adjusted rate of 3.7%

    60% confidence
  • Digital channel first-party sales grew nearly 9%, with same-day delivery increasing by more than 27%

    60% confidence
  • Target Plus achieved nearly 60% growth in first quarter GMV

    60% confidence
  • Capital expenditures were approximately $1 billion in Q1 with full-year expectation of about $5 billion

    60% confidence
  • Comparable sales grew 5.6%, driven by a 4.4% increase in traffic

    60% confidence
  • SG&A expenses increased due to higher investments in payroll, training, and marketing

    60% confidence
  • Company is executing a multiyear strategy to revamp merchandising and store operations including new leadership roles

    60% confidence
  • Company expects more challenging prior-year comparisons and potential cost headwinds in the first half of the year

    60% confidence
  • SG&A expense rate of 21.9% was more than 2 percentage points higher than last year's rate of 19.3%

    60% confidence
  • Net Promoter Scores and satisfaction metrics reached three-year highs following new guest experience initiatives

    60% confidence
  • Growth was broad-based across both stores and digital channels, with notable increases in all six core merchandise categories

    60% confidence
  • Categories like home and apparel have sales still below 2024 levels, indicating areas that need further improvement

    60% confidence
  • 7 new stores opened in Q1 including the 2,000th location, with plans to open more than 30 this year

    60% confidence
  • Net sales were $25.4 billion, a 6.7% increase from last year

    60% confidence
  • Dividend payments were $516 million in Q1, with a 1.8% increase in per share dividend

    60% confidence
  • Adjusted EPS of $1.71 was 32% higher than prior year adjusted EPS

    60% confidence
  • Gross margin rate was 29%, an improvement of 80 basis points from the previous year

    60% confidence
  • Broader operating environment remains uncertain with potential headwinds from consumer sentiment and economic conditions

    60% confidence

Data points we hold from this source

Target Corporation · total store count2000 stores
Target Corporation · same day delivery growth27 percent
Target Corporation · traffic growth4.4 percent
Target Corporation · sga rate21.9 percent
Target Corporation · operating margin4.5 percent
Target Corporation · operating margin prior year adjusted3.7 percent
Target Corporation · margin29.0 percent
Target Corporation · new stores opened7 stores
Target Corporation · gross margin yoy change0.80 percent
Target Corporation · sga rate prior year19.3 percent
Target Corporation · digital first party sales growth9 percent
Target Corporation · dividend payment516 USD
Target Corporation · capex1.0 USD
Target Corporation · comparable sales growth5.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com